Log in

OTCMKTS:QTXB - Quantrx Biomedical Stock Price, Forecast & News

$0.0028
0.00 (0.00 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume125,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:QTXB
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive QTXB News and Ratings via Email

Sign-up to receive the latest news and ratings for QTXB and its competitors with MarketBeat's FREE daily newsletter.


Quantrx Biomedical (OTCMKTS:QTXB) Frequently Asked Questions

What is Quantrx Biomedical's stock symbol?

Quantrx Biomedical trades on the OTCMKTS under the ticker symbol "QTXB."

Has Quantrx Biomedical been receiving favorable news coverage?

News headlines about QTXB stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quantrx Biomedical earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Quantrx Biomedical.

What other stocks do shareholders of Quantrx Biomedical own?

Who are Quantrx Biomedical's key executives?

Quantrx Biomedical's management team includes the folowing people:
  • Dr. Shalom Z. Hirschman, Chairman, CEO & Principal Accounting Officer (Age 83)

How do I buy shares of Quantrx Biomedical?

Shares of QTXB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quantrx Biomedical's stock price today?

One share of QTXB stock can currently be purchased for approximately $0.00.


MarketBeat Community Rating for Quantrx Biomedical (OTCMKTS QTXB)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Quantrx Biomedical and other stocks. Vote "Outperform" if you believe QTXB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTXB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel